# ATTIC - Access To Treat in the Community

> **NCT03797066** · PHASE4 · TERMINATED · sponsor: **King's College Hospital NHS Trust** · enrollment: 13 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** ZEPATIER 50Mg-100Mg Tablet

## Key facts

- **NCT ID:** NCT03797066
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-23
- **Primary completion:** 2020-07-28
- **Final completion:** 2020-11-30
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Changing parameters in HCV management, resulted in poor recruitment; additionally onset of SARS CoV2 resulted in the cessation of all mobile clinical services.
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03797066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03797066, "ATTIC - Access To Treat in the Community". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03797066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*